Immunic to Participate in Scientific Conferences in October
October 4, 2023NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic to Participate in Industry and Investor Conferences in September
September 6, 2023NEW YORK, September 6, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 17, 2023– Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 – – Full Data Readout Expected in April 2025…Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 3, 2023– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective…Immunic to Participate in Investor and Scientific Conferences in August
August 1, 2023NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
July 27, 2023– Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK, July 27, 2023 – Immunic,…Immunic to Participate in Scientific and Investor Conferences in July
June 29, 2023NEW YORK, June 29, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic to Participate in Scientific and Investor Conferences in June
May 30, 2023NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 17, 2023– Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator –…Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach…
